BioSpace News Archive

Akan Biosciences, LLC, a Maryland based, clinical stage biotech company innovating cellular technology and proprietary manufacturing methods to produce stem cell-based therapeutics, announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application for StroMel™, its lead candidate for the treatment of Osteoarthritis of Knee.

The growing prevalence of coronary artery diseases stands as a key factor aiding in expansion of the global antisense and RNAi therapeutics market and is likely to continue so during the forecast period set between 2020 and 2030.

Industrial microbiology encompasses the use of microorganisms and their metabolites for a wide variety of industrial products.

During the course of the 4th quarter, challenges associated with the COVID-19 global pandemic increased and impacted the company’s commercial activity.

ERS Genomics Limited and ZeClinics announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

Ocutrx Technologies, a California-based technology company known for its ORLenz™ surgery augmented reality headset, and the OR-Bot Surgery Visualization Theatre™, has announced that they are expanding from external visualization augmented reality and extended reality techniques to a first-of-class laparoscopic visualization key-hole instrument called “Scopetrx™”, a Wireless Laparoscopic Swivel Camera Tool.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration for its third-generation implantable neurostimulator.

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results and other business highlights and will participate in two upcoming investor conferences.

Clene Inc. announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, received official ANVISA approval in Brazil to commence its multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of CNM-ZnAg liquid solution in a Phase 2 clinical study in acutely symptomatic, non-hospitalized COVID-19 patients.

Luminostics’s Clip COVID Rapid Antigen Test uses a smartphone-based analyzer to obtain results in 30 minutes from nasal swabs in decentralized settings